沛爾生技醫藥股份有限公司
沛爾生技醫藥股份有限公司為免疫細胞療法研發公司。專注於嵌合抗原受體 T 細胞（CAR-T）技術，主要開發針對 B 細胞淋巴瘤與實體腫瘤之新藥。公司具備符合標準之細胞製備廠與研發中心。公司成立於 2017 年，總部位於台灣台北。
該股 RSI(6) 為 18.8，處於超賣區間，短線跌深可能有反彈機會。股價跌破5日、20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=22.1）；MACD 柱狀體為負值，空方動能持續。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -620 | 0 | -99 | -720 |
| 09-23 | -335 | 0 | -54 | -389 |
| 09-22 | -944 | 0 | -47 | -991 |
| 09-21 | -340 | 0 | -76 | -416 |
| 09-18 | -513 | +209 | -54 | -358 |
| 09-17 | -72 | 0 | -143 | -215 |
| 09-16 | -305 | 0 | -227 | -532 |
| 09-15 | -140 | 0 | +8 | -132 |
| 09-14 | -108 | 0 | -67 | -175 |
| 09-11 | -1,009 | 0 | -1 | -1,010 |
| 09-10 | -1,132 | 0 | +6 | -1,125 |
| 09-09 | -6,626 | 0 | +74 | -6,552 |
| 09-08 | +348 | 0 | -470 | -122 |
| 09-07 | +58 | 0 | +374 | +432 |
| 08-26 | -26 | 0 | +1 | -25 |
| 08-25 | +124 | 0 | -92 | +32 |
| 08-24 | +123 | 0 | -40 | +83 |
| 08-21 | +26 | 0 | -17 | +9 |
| 08-20 | +63 | 0 | -31 | +32 |
| 08-19 | +64 | 0 | -16 | +48 |
| 08-18 | +76 | 0 | -15 | +60 |
| 08-17 | +6 | 0 | -190 | -185 |
| 08-14 | +90 | 0 | -18 | +72 |
| 08-13 | +20 | 0 | +5 | +25 |
| 08-12 | +43 | 0 | 0 | +43 |
| 08-11 | +47 | 0 | -24 | +23 |
| 08-10 | +1 | 0 | +1 | +2 |
| 08-07 | -17 | 0 | 0 | -17 |
| 08-06 | +30 | 0 | -10 | +20 |
| 08-05 | +93 | 0 | -14 | +79 |
| 08-04 | +45 | 0 | -2 | +43 |
| 08-03 | +17 | 0 | -3 | +14 |
| 07-31 | -38 | 0 | 0 | -38 |
| 07-30 | -45 | 0 | -2 | -47 |
| 07-29 | +16 | 0 | +4 | +20 |
| 07-28 | +13 | 0 | +2 | +15 |
| 07-27 | +1 | 0 | 0 | +1 |
| 07-24 | 0 | 0 | +3 | +2 |
| 07-23 | +32 | 0 | 0 | +32 |
| 07-22 | +18 | 0 | 0 | +18 |
| 07-21 | -64 | 0 | -3 | -67 |
| 07-20 | +33 | 0 | -4 | +29 |
| 07-17 | +51 | 0 | +5 | +56 |
| 07-16 | +190 | 0 | -14 | +175 |
| 07-15 | +280 | 0 | +10 | +291 |
| 07-14 | +65 | 0 | -1 | +64 |
| 07-13 | -24 | 0 | -1 | -25 |
| 07-09 | -59 | 0 | -1 | -60 |
| 07-08 | +123 | 0 | 0 | +123 |
| 07-07 | +63 | 0 | 0 | +63 |
| 07-06 | -11 | 0 | +3 | -8 |
| 07-03 | +45 | 0 | +1 | +46 |
| 07-02 | -56 | 0 | 0 | -56 |
| 07-01 | +26 | 0 | -1 | +26 |
| 06-30 | +1 | 0 | -1 | 0 |
| 06-29 | +3 | 0 | 0 | +3 |
| 06-26 | 0 | 0 | -3 | -3 |
| 06-25 | -18 | 0 | +1 | -17 |
| 06-24 | -27 | 0 | 0 | -26 |
| 06-22 | -69 | 0 | +1 | -68 |
| 06-18 | +171 | 0 | -14 | +157 |
| 06-17 | +26 | 0 | +13 | +39 |
| 06-16 | +85 | 0 | 0 | +85 |
| 06-15 | +13 | 0 | 0 | +12 |
| 06-12 | +19 | 0 | +7 | +26 |
| 06-10 | +69 | 0 | 0 | +69 |
| 06-09 | +18 | 0 | -1 | +17 |
| 06-08 | +66 | 0 | 0 | +66 |
| 06-04 | -20 | 0 | -1 | -21 |
| 06-03 | -11 | 0 | 0 | -11 |
| 06-02 | -28 | 0 | 0 | -28 |
| 06-01 | -36 | 0 | -2 | -37 |
| 05-29 | -85 | 0 | -1 | -86 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/08 | 650 萬 | +157.8% | +164.7% |
| 2026/07 | 252 萬 | -23.1% | -22.6% |
| 2026/06 | 328 萬 | +21.7% | +50.2% |
| 2026/05 | 269 萬 | -9.4% | +18.8% |
| 2026/04 | 297 萬 | +21.1% | +107.9% |
| 2026/03 | 245 萬 | +24.5% | +74.5% |
| 2026/02 | 197 萬 | -0.4% | +61.2% |
| 2026/01 | 198 萬 | -14.6% | -78.3% |
| 2025/12 | 232 萬 | +36.9% | +26.4% |
| 2025/11 | 169 萬 | -21.4% | +8.0% |
| 2025/10 | 215 萬 | +14.1% | +53.5% |
| 2025/09 | 189 萬 | - | +8.4% |